Cargando…

Evaluation of Surgical Therapy in Advanced Thymic Tumors

SIMPLE SUMMARY: A complete resection of thymic tumors is known to be the most important prognostic factor, but it is often difficult to perform, especially in advanced stages. In this study, patients with advanced thymic tumors who underwent radical resection were examined retrospectively. The prima...

Descripción completa

Detalles Bibliográficos
Autores principales: Markowiak, Till, Ansari, Mohammed Khalid Afeen, Neu, Reiner, Schalke, Berthold, Marx, Alexander, Hofmann, Hans-Stefan, Ried, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471625/
https://www.ncbi.nlm.nih.gov/pubmed/34572742
http://dx.doi.org/10.3390/cancers13184516
_version_ 1784574516000718848
author Markowiak, Till
Ansari, Mohammed Khalid Afeen
Neu, Reiner
Schalke, Berthold
Marx, Alexander
Hofmann, Hans-Stefan
Ried, Michael
author_facet Markowiak, Till
Ansari, Mohammed Khalid Afeen
Neu, Reiner
Schalke, Berthold
Marx, Alexander
Hofmann, Hans-Stefan
Ried, Michael
author_sort Markowiak, Till
collection PubMed
description SIMPLE SUMMARY: A complete resection of thymic tumors is known to be the most important prognostic factor, but it is often difficult to perform, especially in advanced stages. In this study, patients with advanced thymic tumors who underwent radical resection were examined retrospectively. The primary endpoint was defined as the postoperative resection status. Secondary endpoints included postoperative morbidity, mortality, and survival. In tumor stages III a microscopic complete resection was achieved in 53.3% of patients. In stages IV a macroscopic complete resection was documented in 76.7% of patients. Surgical revision was necessary in 17.8% of patients. In-hospital mortality was 2.7%. The 5-year survival rate of all patients was 61.3%. In particular, median survival after macroscopic incomplete resection was significantly short. Advanced thymic tumors can be resected with an acceptable risk of complications and low mortality. In stage III as well as in stage IV the promising survival rates are dependent on the resection-status. ABSTRACT: A complete resection of thymic tumors is known to be the most important prognostic factor, but it is often difficult to perform, especially in advanced stages. In this study, 73 patients with advanced thymic tumors of UICC stages III and IV who underwent radical resection were examined retrospectively. The primary endpoint was defined as the postoperative resection status. Secondary endpoints included postoperative morbidity, mortality, recurrence/progression-free, and overall survival. In total, 31.5% of patients were assigned to stage IIIa, 9.6% to stage IIIb, 47.9% to stage IVa, and 11% to stage IVb. In stages III a R0 resection was achieved in 53.3% of patients. In stages IV a R0/R1 resection was documented in 76.7% of patients. Surgical revision was necessary in 17.8% of patients. In-hospital mortality was 2.7%. Median recurrence/progression-free interval was 43 months (p = 0.19) with an overall survival of 79 months. The 5-year survival rate was 61.3%, respectively. Median survival after R2 resection was 25 months, significantly shorter than after R0 or R1 resection (115 months; p = 0.004). Advanced thymic tumors can be resected with an acceptable risk of complications and low mortality. In stage III as well as in stage IV the promising survival rates are dependent on the resection-status.
format Online
Article
Text
id pubmed-8471625
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84716252021-09-28 Evaluation of Surgical Therapy in Advanced Thymic Tumors Markowiak, Till Ansari, Mohammed Khalid Afeen Neu, Reiner Schalke, Berthold Marx, Alexander Hofmann, Hans-Stefan Ried, Michael Cancers (Basel) Article SIMPLE SUMMARY: A complete resection of thymic tumors is known to be the most important prognostic factor, but it is often difficult to perform, especially in advanced stages. In this study, patients with advanced thymic tumors who underwent radical resection were examined retrospectively. The primary endpoint was defined as the postoperative resection status. Secondary endpoints included postoperative morbidity, mortality, and survival. In tumor stages III a microscopic complete resection was achieved in 53.3% of patients. In stages IV a macroscopic complete resection was documented in 76.7% of patients. Surgical revision was necessary in 17.8% of patients. In-hospital mortality was 2.7%. The 5-year survival rate of all patients was 61.3%. In particular, median survival after macroscopic incomplete resection was significantly short. Advanced thymic tumors can be resected with an acceptable risk of complications and low mortality. In stage III as well as in stage IV the promising survival rates are dependent on the resection-status. ABSTRACT: A complete resection of thymic tumors is known to be the most important prognostic factor, but it is often difficult to perform, especially in advanced stages. In this study, 73 patients with advanced thymic tumors of UICC stages III and IV who underwent radical resection were examined retrospectively. The primary endpoint was defined as the postoperative resection status. Secondary endpoints included postoperative morbidity, mortality, recurrence/progression-free, and overall survival. In total, 31.5% of patients were assigned to stage IIIa, 9.6% to stage IIIb, 47.9% to stage IVa, and 11% to stage IVb. In stages III a R0 resection was achieved in 53.3% of patients. In stages IV a R0/R1 resection was documented in 76.7% of patients. Surgical revision was necessary in 17.8% of patients. In-hospital mortality was 2.7%. Median recurrence/progression-free interval was 43 months (p = 0.19) with an overall survival of 79 months. The 5-year survival rate was 61.3%, respectively. Median survival after R2 resection was 25 months, significantly shorter than after R0 or R1 resection (115 months; p = 0.004). Advanced thymic tumors can be resected with an acceptable risk of complications and low mortality. In stage III as well as in stage IV the promising survival rates are dependent on the resection-status. MDPI 2021-09-08 /pmc/articles/PMC8471625/ /pubmed/34572742 http://dx.doi.org/10.3390/cancers13184516 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Markowiak, Till
Ansari, Mohammed Khalid Afeen
Neu, Reiner
Schalke, Berthold
Marx, Alexander
Hofmann, Hans-Stefan
Ried, Michael
Evaluation of Surgical Therapy in Advanced Thymic Tumors
title Evaluation of Surgical Therapy in Advanced Thymic Tumors
title_full Evaluation of Surgical Therapy in Advanced Thymic Tumors
title_fullStr Evaluation of Surgical Therapy in Advanced Thymic Tumors
title_full_unstemmed Evaluation of Surgical Therapy in Advanced Thymic Tumors
title_short Evaluation of Surgical Therapy in Advanced Thymic Tumors
title_sort evaluation of surgical therapy in advanced thymic tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471625/
https://www.ncbi.nlm.nih.gov/pubmed/34572742
http://dx.doi.org/10.3390/cancers13184516
work_keys_str_mv AT markowiaktill evaluationofsurgicaltherapyinadvancedthymictumors
AT ansarimohammedkhalidafeen evaluationofsurgicaltherapyinadvancedthymictumors
AT neureiner evaluationofsurgicaltherapyinadvancedthymictumors
AT schalkeberthold evaluationofsurgicaltherapyinadvancedthymictumors
AT marxalexander evaluationofsurgicaltherapyinadvancedthymictumors
AT hofmannhansstefan evaluationofsurgicaltherapyinadvancedthymictumors
AT riedmichael evaluationofsurgicaltherapyinadvancedthymictumors